Kalkine : Theravance Biopharma in Nasdaq Top 100

2 min read | June 03, 2025 02:23 PM PDT | By Team Kalkine Media

Highlights

  • Theravance Biopharma operates in the biopharmaceutical sector, listed on Nasdaq.
  • The company is part of key market indexes, including Nasdaq and other biotechnology-related indexes.
  • Recent filings reveal a new position established in Theravance Biopharma’s shares during the last quarter.

Theravance Biopharma, (NASDAQ:TBPH) a notable biopharmaceutical company listed on Nasdaq, is recognized among the Nasdaq Top 100. Its inclusion in prominent biotechnology-focused indexes underscores its role in advancing innovative therapies and contributing to the healthcare and biotech sectors.

Recent Position Changes in Theravance Biopharma Shares

During the last quarter, regulatory filings disclosed that an institutional fund took a stake in Theravance Biopharma. This activity indicates renewed attention on the company’s stock within Nasdaq and associated biotechnology indexes. The exact quantity of shares was specified in the report, marking a notable transaction in the market.

Market Significance of Theravance Biopharma’s Index Listings

Being part of Nasdaq and several specialized biotech indexes positions Theravance Biopharma alongside peers focusing on pharmaceuticals and medical innovation. These indexes serve as benchmarks for monitoring companies advancing medical therapies and pharmaceutical development, with Theravance maintaining a recognized role in this group

Sector and Theravance Biopharma’s Position

Theravance Biopharma operates within a dynamic biopharmaceutical industry characterized by research and development of treatment solutions. Inclusion in prominent market indexes underlines its market relevance and aligns the company with industry trends seen in Nasdaq and biotechnology sectors.

Index Tracking and Institutional Activity

The involvement of major funds in Theravance Biopharma (NASDAQ:TBPH) shares, as reflected in regulatory disclosures, often signals ongoing market interest in biopharmaceutical companies listed on Nasdaq. These actions contribute to the company’s visibility within biotechnology-focused market indexes and emphasize its participation in sector-wide movements.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next